



Leveraging Patient-Derived Natural History Data When Designing Clinical Trials

FDA Workshop
Developing Therapies for
Primary Mitochondrial Diseases:
Bridging the Gaps

September 6, 2019

Philip E. Yeske, Ph.D.
Science & Alliance Officer
UMDF

Mitochondrial Disease Ecosystem







MDCR Current Status

- June 2019: ~2,500 registrants
- Single static survey
 - ~100 Q's/~50K Responses
 - Baseline demographics
 - Diagnostic State
 - Opinions on patient-centered drug development
- International: 46 countries represented!
 - ~90% from the US

% Registrants




Biological Gender





MDCR Data Snapshots

Self-Reported Diagnostic State



Sample of Mitochondrial Disease Types Currently Represented in MDCR

Mitochondrial DNA Mutation Syndromes

LHON, LHON+, MELAS, MERRF, MIDD, MILS, NARP

Mitochondrial DNA Deletion Syndromes

CPEO, KSS, ADOA

Nuclear Gene Disorders

Leigh's, MNGIE, Alper's, SANDO

Biochemical Disorders

Complex I, Complex II, Complex III, Complex IV, Complex V, CoQ Deficiency

System-Based Disorders

Encephalomyopathy, Encephalopathy, Mitochondrial Myopathy

Near-Term Growth Initiatives

- Inter-connectivity
 - Ensuring MDCR can connect/share with other data repositories
- Data Collection Diversification
 - Longitudinal Patient-Reported Outcomes
 - Patient Genetic Data
 - Patient Biosamples & Virtual Repository
- Globalization
 - Establishing a network platform with international PAG partners
 - Ensure we are identifying and characterizing as many patients as possible to improve readiness for clinical trials